STAT

Opinion: The NIH should follow the National Science Foundation’s lead on stopping gender violence in science

It's time for @NIH, the world's largest funder of science, to create strong rules about gender violence in the projects it supports.
NIH headquarters in Bethesda, Md.

As part of the National Science Foundation’s effort to prevent gender violence in science, its director, France A. Córdova, recently announced new terms and conditions for reporting gender violence to the organization. It is the kind of clear and bold approach that the National Institutes of Health should be taking. Instead, the NIH is sticking with its weak “guidance” on anti-sexual harassment, shirking its responsibility and placing the burden for action on survivors, though it did launch a new website on the topic.

The new NSF policy requires institutions to notify the foundation when a principal investigator or co-principal investigator is facing administrative action, administrative leave, a finding or determination of responsibility, or is under active investigation related to sexual harassment, other forms of harassment, or sexual assault. In striving for clarity, the NSF also defined those italicized terms (listed below).

The new policy, which goes into effect Oct.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A J&J Cough Syrup, A Pfizer And Moderna Patent Suit, And More
A Johnson & Johnson children’s cough syrup found to contain unsafe levels of a toxic industrial solvent was sold in six African countries.
STAT1 min read
USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.

Related